Atovaquone-d4

• Description:

  Atovaquone-d4 is the deuterium labeled Atovaquone. Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia[1].

• UNSPSC:

  12352005

• Target:

  Isotope-Labeled Compounds; Parasite

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection; Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Purity:

  99.8

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1C2=C(C(C(O)=C1[C@@H]3CC[C@@H](C4=CC=C(Cl)C=C4)CC3)=O)C([2H])=C([2H])C([2H])=C2[2H]

• Molecular Formula:

  C22H15D4ClO3

• Molecular Weight:

  370.86

• References & Citations:

  [1]Looareesuwan, S., et al., Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg, 1996. 54 (1) : p. 62-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• Isoform:

  Plasmodium

• CAS Number:

  [2070015-14-2]